Bio-Rad, Ciphergen, Sentigen, Invitrogen, Thermo Fisher Scientific, Waters, Advion, ProteoPure, Axxora, Genetix, Sigma-Aldrich, Rules-Based Medicine, Multiplex Biosciences, Ludesi, John Hopkins, GenoLogics, Pressure BioSciences | GenomeWeb
Bio-Rad Closes Purchase of Ciphergen Proteomic Tools Business
 
Two weeks after its anticipated closing date, Bio-Rad’s purchase of Ciphergen’s life science research business for $20 million in cash was finalized this week.
 
Bio-Rad is also making a $3 million equity stake in Ciphergen as part of the deal.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.